logo
logo

Cadenza Bio, Inc. Secures $2.44M In Oversubscribed Series Seed Financing

Dec 14, 2023•over 1 year ago

Amount Raised

$2.44 Million

Round Type

seed

OklahomaTherapeuticsHealth CareBiotechnology

Investors

Illinois VenturesBoyd Street VenturesCortado VenturesOklahoma Life Science FundPlains Ventures

Description

Cadenza Bio, Inc. (Cadenza), a privately-held biotechnology company focused on developing novel small molecule compounds for demyelinating and inflammatory diseases, has announced the initial closing of an oversubscribed $2.44M Series Seed financing

Company Information

Company

Cadenza Bio

Location

Oklahoma, United States

About

Cadenza Bio, Inc. was founded in 2022 to accelerate and support the development of a series of novel, and highly selective Estrogen Receptor β (ERβ) targeting small-molecule compounds. We are dedicated to advancing therapeutic drugs that will make a meaningful impact in the lives of patients suffering from debilitating diseases. For more information please visit www.cadenza.bio SOURCE Cadenza Bio, Inc.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Related People